|
US6706474B1
(en)
|
2000-06-27 |
2004-03-16 |
Board Of Trustees Of The University Of Illinois |
Nucleic acid enzyme biosensors for ions
|
|
ATE427948T1
(de)
|
2001-04-24 |
2009-04-15 |
Purdue Research Foundation |
Folat-mimetika und deren folatrezeptorbindende konjugate
|
|
US20030134433A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Nanomix, Inc. |
Electronic sensing of chemical and biological agents using functionalized nanostructures
|
|
US20060228723A1
(en)
*
|
2002-01-16 |
2006-10-12 |
Keith Bradley |
System and method for electronic sensing of biomolecules
|
|
US20070178477A1
(en)
*
|
2002-01-16 |
2007-08-02 |
Nanomix, Inc. |
Nanotube sensor devices for DNA detection
|
|
EP1572902B1
(en)
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
ATE556714T1
(de)
|
2002-02-01 |
2012-05-15 |
Life Technologies Corp |
Doppelsträngige oligonukleotide
|
|
US6890719B2
(en)
|
2002-05-10 |
2005-05-10 |
The Board Of Trustess Of The University Of Illinois |
Fluorescence based biosensor
|
|
CA2484640C
(en)
*
|
2002-05-15 |
2012-01-17 |
Endocyte, Inc. |
Vitamin-mitomycin conjugates
|
|
US7948041B2
(en)
|
2005-05-19 |
2011-05-24 |
Nanomix, Inc. |
Sensor having a thin-film inhibition layer
|
|
WO2004069159A2
(en)
|
2003-01-27 |
2004-08-19 |
Endocyte, Inc. |
Vitamin receptor binding drug delivery conjugates
|
|
ES2702942T3
(es)
*
|
2003-04-17 |
2019-03-06 |
Alnylam Pharmaceuticals Inc |
Agentes de ARNi modificados
|
|
US7851615B2
(en)
*
|
2003-04-17 |
2010-12-14 |
Alnylam Pharmaceuticals, Inc. |
Lipophilic conjugated iRNA agents
|
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
US8017762B2
(en)
*
|
2003-04-17 |
2011-09-13 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
US7723509B2
(en)
|
2003-04-17 |
2010-05-25 |
Alnylam Pharmaceuticals |
IRNA agents with biocleavable tethers
|
|
US8969314B2
(en)
*
|
2003-07-31 |
2015-03-03 |
Regulus Therapeutics, Inc. |
Methods for use in modulating miR-122a
|
|
GB2424887B
(en)
|
2003-11-26 |
2008-05-21 |
Univ Massachusetts |
Sequence-specific inhibition of small RNA function
|
|
EP2290073A3
(en)
|
2004-05-28 |
2011-08-31 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
|
US8153111B2
(en)
*
|
2004-06-18 |
2012-04-10 |
Ceramoptec Industries, Inc. |
Photo-triggered release of active substances from dendrimer-photosensitizer complexes
|
|
CN101098854B
(zh)
*
|
2004-07-23 |
2012-12-05 |
恩多塞特公司 |
二价连接体及其轭合物
|
|
EP1791567B1
(en)
|
2004-08-10 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
Chemically modified oligonucleotides
|
|
HUE033977T2
(en)
|
2004-08-23 |
2018-02-28 |
Sylentis Sau |
Treatment of eye disorders with siRNAs characterized by increased intraocular pressure
|
|
EP2377873B1
(en)
*
|
2004-09-24 |
2014-08-20 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of ApoB and uses thereof
|
|
EP2302055B1
(en)
|
2004-11-12 |
2014-08-27 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
|
US20060185027A1
(en)
*
|
2004-12-23 |
2006-08-17 |
David Bartel |
Systems and methods for identifying miRNA targets and for altering miRNA and target expression
|
|
TW200639252A
(en)
*
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular hypertension targets
|
|
CN101175757B
(zh)
*
|
2005-03-16 |
2012-11-14 |
恩多塞特公司 |
蝶酸及其缀合物的合成和纯化
|
|
US8153435B1
(en)
|
2005-03-30 |
2012-04-10 |
Tracer Detection Technology Corp. |
Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
|
|
CA2609142C
(en)
|
2005-05-27 |
2016-02-09 |
Fondazione Centro San Raffaele Del Monte Tabor |
Therapeutic gene vectors comprising mirna target sequences
|
|
US9290617B2
(en)
*
|
2005-07-06 |
2016-03-22 |
Molly S. Shoichet |
Method of biomolecule immobilization on polymers using click-type chemistry
|
|
US7892734B2
(en)
|
2005-08-11 |
2011-02-22 |
The Board Of Trustees Of The University Of Illinois |
Aptamer based colorimetric sensor systems
|
|
BRPI0615354A2
(pt)
*
|
2005-08-19 |
2011-05-17 |
Endocyte, Inc. |
conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
|
|
EP2382995A3
(en)
*
|
2005-08-19 |
2013-09-25 |
Endocyte, Inc. |
Ligand conjugates of Vinca alkaloids, analogs and derivatives
|
|
EP1931780B1
(en)
*
|
2005-08-29 |
2016-01-06 |
Regulus Therapeutics Inc. |
Antisense compounds having enhanced anti-microrna activity
|
|
US8501703B2
(en)
*
|
2005-08-30 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
GB0521351D0
(en)
*
|
2005-10-20 |
2005-11-30 |
Genomica Sau |
Modulation of TRPV expression levels
|
|
GB0521716D0
(en)
*
|
2005-10-25 |
2005-11-30 |
Genomica Sau |
Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
|
|
JP4538522B2
(ja)
|
2005-11-25 |
2010-09-08 |
コーリー ファーマシューティカル ゲーエムベーハー |
免疫刺激性オリゴリボヌクレオチド
|
|
US7799554B2
(en)
|
2006-03-16 |
2010-09-21 |
The Board Of Trustees Of The University Of Illinois |
Lateral flow devices
|
|
WO2007109350A2
(en)
*
|
2006-03-23 |
2007-09-27 |
California Institute Of Technology |
Modulation of innate immunity receptors' signaling by micrornas mir-146a and mir-146b
|
|
EP2007888A2
(en)
|
2006-04-03 |
2008-12-31 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
SG10201406016SA
(en)
|
2006-04-03 |
2014-11-27 |
Stella Aps |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
US20090023221A1
(en)
*
|
2006-05-19 |
2009-01-22 |
Exigon A/S |
Oligonucleotide probes useful for detection and analysis of microrna precursors
|
|
WO2008033285A2
(en)
*
|
2006-09-15 |
2008-03-20 |
The Trustees Of Culumbia University In The City Of New York |
Delivery of double-stranded rna into the central nervous system
|
|
AU2007299804A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
MiR-200 regulated genes and pathways as targets for therapeutic intervention
|
|
GB0624302D0
(en)
*
|
2006-12-05 |
2007-01-17 |
Istituto Superiore Di Sanito |
Micro RNA
|
|
US8415461B2
(en)
*
|
2007-01-19 |
2013-04-09 |
The Board Of Trustees Of The University Of Illinois |
Amphiphilic substances and functionalized lipid vesicles including the same
|
|
US20100104626A1
(en)
*
|
2007-02-16 |
2010-04-29 |
Endocyte, Inc. |
Methods and compositions for treating and diagnosing kidney disease
|
|
US20100292301A1
(en)
*
|
2007-02-28 |
2010-11-18 |
Elena Feinstein |
Novel sirna structures
|
|
AU2008224988A1
(en)
|
2007-03-14 |
2008-09-18 |
Endocyte, Inc. |
Binding ligand linked drug delivery conjugates of tubulysins
|
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
|
US8470791B2
(en)
|
2007-03-22 |
2013-06-25 |
Santaris Pharma A/S |
RNA antagonist compounds for the inhibition of Apo-B100 expression
|
|
CA2685127C
(en)
|
2007-04-23 |
2019-01-08 |
Alnylam Pharmaceuticals, Inc. |
Glycoconjugates of rna interference agents
|
|
WO2009002944A1
(en)
*
|
2007-06-22 |
2008-12-31 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
|
US20090082297A1
(en)
*
|
2007-06-25 |
2009-03-26 |
Lioy Daniel T |
Compositions and Methods for Regulating Gene Expression
|
|
CN101784565B
(zh)
|
2007-06-25 |
2014-12-10 |
恩多塞特公司 |
含有亲水性间隔区接头的共轭物
|
|
US20100292099A1
(en)
*
|
2007-08-23 |
2010-11-18 |
Keren Pharmaceutical, Inc. |
Targeting of rna with external guide sequences
|
|
WO2009036332A1
(en)
|
2007-09-14 |
2009-03-19 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
|
RU2487716C2
(ru)
*
|
2007-10-03 |
2013-07-20 |
Кварк Фармасьютикалс, Инк. |
Новые структуры малых интерферирующих рнк (sirna)
|
|
EP2623599B1
(en)
*
|
2007-10-04 |
2019-01-02 |
Roche Innovation Center Copenhagen A/S |
Micromirs
|
|
CN101909441B
(zh)
|
2007-10-25 |
2015-05-13 |
恩多塞特公司 |
微管蛋白抑制剂及其制备方法
|
|
US8211867B2
(en)
|
2007-10-29 |
2012-07-03 |
Regulus Therapeutics Inc. |
Targeting microRNAs for the treatment of liver cancer
|
|
MX2010005055A
(es)
*
|
2007-11-09 |
2010-06-25 |
Isis Pharmaceuticals Inc |
Modulacion de la expresion del factor 7.
|
|
KR20100099158A
(ko)
|
2007-11-09 |
2010-09-10 |
보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 |
심근세포 생존과 심장 회복을 제어하는 ＭＩＲ-15 집단의 마이크로ＲＮＡｓ
|
|
WO2009070805A2
(en)
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
|
WO2009082606A2
(en)
*
|
2007-12-04 |
2009-07-02 |
Alnylam Pharmaceuticals, Inc. |
Folate conjugates
|
|
WO2009073809A2
(en)
*
|
2007-12-04 |
2009-06-11 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
AU2014208251B2
(en)
*
|
2007-12-04 |
2016-07-14 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
|
US20110105584A1
(en)
*
|
2007-12-12 |
2011-05-05 |
Elena Feinstein |
Rtp80il sirna compounds and methods of use thereof
|
|
EP2242854A4
(en)
*
|
2008-01-15 |
2012-08-15 |
Quark Pharmaceuticals Inc |
COMPOUNDS AND USES THEREOF
|
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
|
CA2717026A1
(en)
*
|
2008-02-28 |
2009-09-03 |
The Ohio State University Research Foundation |
Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
|
|
CA2717792A1
(en)
*
|
2008-03-07 |
2009-09-11 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
CA2718765A1
(en)
*
|
2008-03-20 |
2009-09-24 |
Quark Pharmaceuticals, Inc. |
Novel sirna compounds for inhibiting rtp801
|
|
CA2721183C
(en)
|
2008-04-11 |
2019-07-16 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
EP2285385A4
(en)
*
|
2008-04-15 |
2013-01-16 |
Quark Pharmaceuticals Inc |
COMPOUNDS BASED ON RNSI TO INHIBIT NRF2
|
|
WO2009137807A2
(en)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
|
EP2310507A4
(en)
*
|
2008-07-08 |
2013-03-20 |
David Gladstone Inst |
METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
|
|
WO2010012667A1
(en)
|
2008-08-01 |
2010-02-04 |
Santaris Pharma A/S |
Micro-rna mediated modulation of colony stimulating factors
|
|
EP2414521B1
(en)
*
|
2009-03-31 |
2016-10-26 |
The General Hospital Corporation |
Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders
|
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
|
WO2010134992A2
(en)
*
|
2009-05-18 |
2010-11-25 |
Chemgenes Corporation |
Synthesis labile base protected - modified deoxy & modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis
|
|
CN105935365B
(zh)
|
2009-05-20 |
2018-12-21 |
Eth苏黎世公司 |
用于代谢紊乱的靶向微小rna
|
|
WO2010141511A2
(en)
|
2009-06-01 |
2010-12-09 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent rna interference, compositions and methods of use thereof
|
|
SG176716A1
(en)
*
|
2009-06-08 |
2012-01-30 |
Miragen Therapeutics |
CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
|
|
EP2456870A1
(en)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
|
US9334495B2
(en)
|
2009-11-25 |
2016-05-10 |
Elitechgroup B.V. |
Minor groove binder (MGB)-oligonucleotide miRNA antagonists
|
|
AU2010324658A1
(en)
|
2009-11-26 |
2012-05-03 |
Quark Pharmaceuticals, Inc. |
siRNA compounds comprising terminal substitutions
|
|
WO2011072082A2
(en)
*
|
2009-12-09 |
2011-06-16 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
|
US20130059906A1
(en)
*
|
2010-02-17 |
2013-03-07 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions for influencing tumors using microrna-185 as a tumor suppressor
|
|
EP2608812B1
(en)
|
2010-08-25 |
2018-08-15 |
The General Hospital Corporation |
Nucleic acids targeting mir-33 micrornas for regulating lipid metabolism
|
|
WO2012030745A1
(en)
*
|
2010-08-30 |
2012-03-08 |
Access Pharmaecuticals, Inc |
MULTIVITAMIN TARGETING OF RNAi THERAPEUTICS
|
|
AU2011317846B2
(en)
*
|
2010-10-21 |
2015-07-09 |
Deutsches Krebsforschungszentrum |
Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of its capsid
|
|
KR101913232B1
(ko)
*
|
2010-10-27 |
2018-10-30 |
큐알엔에이, 인크. |
인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료
|
|
WO2012059612A1
(es)
|
2010-11-04 |
2012-05-10 |
Consejo Superior De Investigaciones Científicas (Csic) |
Derivados de pequeños arn de interferencia y su uso
|
|
AU2011338682B2
(en)
*
|
2010-12-06 |
2017-04-27 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising threose modifications
|
|
US10463687B2
(en)
|
2011-01-20 |
2019-11-05 |
Cornell University |
Treatments for retinal disorders
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
HUE031595T2
(en)
|
2011-04-25 |
2017-07-28 |
Regulus Therapeutics Inc |
Micro RNA Compounds s Methods for Modulating Mir-21 Activity
|
|
WO2013033230A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
|
TWI516267B
(zh)
|
2011-11-07 |
2016-01-11 |
臺北榮民總醫院 |
抑制癌症或腫瘤細胞之類癌幹細胞特性及抗化學及放射治療特性的醫藥組合物
|
|
WO2013071079A1
(en)
|
2011-11-09 |
2013-05-16 |
President And Fellows Of Harvard College |
Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics
|
|
US10080805B2
(en)
|
2012-02-24 |
2018-09-25 |
Purdue Research Foundation |
Cholecystokinin B receptor targeting for imaging and therapy
|
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
|
EA030211B1
(ru)
|
2012-04-25 |
2018-07-31 |
Регьюлэс Терапьютикс Инк. |
Соединения на основе микрорнк и способы модулирования активности mir-21
|
|
US9163235B2
(en)
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
|
AU2012389270B2
(en)
|
2012-09-05 |
2018-11-08 |
Sylentis S.A.U. |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
UA116639C2
(uk)
|
2012-10-09 |
2018-04-25 |
Рег'Юлес Терап'Ютікс Інк. |
Способи лікування синдрому альпорта
|
|
AR092982A1
(es)
|
2012-10-11 |
2015-05-13 |
Isis Pharmaceuticals Inc |
Modulacion de la expresion de receptores androgenicos
|
|
BR112015008365A2
(pt)
|
2012-10-16 |
2017-07-04 |
Endocyte Inc |
composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
US10731161B2
(en)
|
2013-03-11 |
2020-08-04 |
The Johns Hopkins University |
Influenza-activated constructs and methods of use thereof
|
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
|
US10590161B2
(en)
|
2013-03-15 |
2020-03-17 |
Modernatx, Inc. |
Ion exchange purification of mRNA
|
|
WO2014152027A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Manufacturing methods for production of rna transcripts
|
|
EP2971165A4
(en)
|
2013-03-15 |
2016-11-23 |
Moderna Therapeutics Inc |
DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
|
|
WO2014140856A2
(en)
|
2013-03-15 |
2014-09-18 |
Graham Lord |
Mir-142 and antagonists thereof for treating disease
|
|
US9840533B2
(en)
|
2013-04-29 |
2017-12-12 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
DK2992098T3
(da)
|
2013-05-01 |
2019-06-17 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
|
|
HUE048738T2
(hu)
|
2013-06-27 |
2020-08-28 |
Roche Innovation Ct Copenhagen As |
Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
|
|
CA2917348A1
(en)
|
2013-07-11 |
2015-01-15 |
Moderna Therapeutics, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
|
US10144928B2
(en)
|
2013-08-23 |
2018-12-04 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising positional modifications
|
|
EP2845607A1
(en)
*
|
2013-09-09 |
2015-03-11 |
University of Vienna |
Antisense oligonucleotides with improved pharmacokinetic properties
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
US9994846B2
(en)
|
2013-10-25 |
2018-06-12 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
|
CA2926599C
(en)
|
2013-11-05 |
2021-05-04 |
Hill's Pet Nutrition, Inc. |
Methods and compositions for improving kidney function
|
|
SI3071696T1
(sl)
|
2013-11-22 |
2019-11-29 |
Mina Therapeutics Ltd |
C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
|
|
CA2936158C
(en)
|
2014-02-05 |
2023-06-13 |
Yeda Research And Development Co. Ltd. |
Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease
|
|
US10011837B2
(en)
|
2014-03-04 |
2018-07-03 |
Sylentis Sau |
SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
|
EA036496B1
(ru)
|
2014-05-01 |
2020-11-17 |
Ионис Фармасьютикалз, Инк. |
Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
|
|
BR112016022742B1
(pt)
|
2014-05-01 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Composto químico, composição compreendendo o composto e uso dos mesmos
|
|
US9382540B2
(en)
|
2014-05-01 |
2016-07-05 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
US10407683B2
(en)
|
2014-07-16 |
2019-09-10 |
Modernatx, Inc. |
Circular polynucleotides
|
|
KR20170033439A
(ko)
|
2014-08-07 |
2017-03-24 |
레굴루스 테라퓨틱스 인크 |
대사 장애에 대한 마이크로rna의 표적화
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
KR102545316B1
(ko)
|
2014-11-10 |
2023-06-22 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
|
|
KR102599712B1
(ko)
|
2015-04-22 |
2023-11-09 |
미나 테라퓨틱스 리미티드 |
C/EBP 알파 saRNA 조성물 및 사용 방법
|
|
KR20190118688A
(ko)
|
2015-06-05 |
2019-10-18 |
미라젠 세러퓨틱스 인코포레이티드 |
피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제
|
|
MX2018000412A
(es)
|
2015-07-10 |
2018-03-14 |
Ionis Pharmaceuticals Inc |
Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
|
|
WO2017035278A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
EP3350333B2
(en)
|
2015-09-17 |
2025-08-06 |
ModernaTX, Inc. |
Polynucleotides containing a stabilizing tail region
|
|
WO2017049286A1
(en)
*
|
2015-09-17 |
2017-03-23 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a morpholino linker
|
|
CN108513588A
(zh)
|
2015-09-24 |
2018-09-07 |
Ionis制药公司 |
Kras表达的调节剂
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
PL4119569T3
(pl)
|
2015-11-06 |
2024-11-18 |
Ionis Pharmaceuticals, Inc. |
Sprzężone związki antysensowne do zastosowania w terapii
|
|
EP3181698A1
(en)
|
2015-12-16 |
2017-06-21 |
European Molecular Biology Laboratory (EMBL) |
Microrna mir-142 as stem cell marker
|
|
CA3011946A1
(en)
|
2016-03-07 |
2017-09-14 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
WO2017223176A1
(en)
|
2016-06-24 |
2017-12-28 |
Modernatx, Inc. |
Methods and apparatus for filtration
|
|
EP3484524B1
(en)
|
2016-07-15 |
2022-11-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of smn2
|
|
SG11201901841TA
(en)
|
2016-09-02 |
2019-03-28 |
Arrowhead Pharmaceuticals Inc |
Targeting ligands
|
|
US11400161B2
(en)
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
CA3041761A1
(en)
*
|
2016-10-31 |
2018-05-03 |
Gifu University |
Double-stranded nucleic acid molecule and use thereof
|
|
CA3043768A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
|
WO2019089765A1
(en)
|
2017-11-01 |
2019-05-09 |
Arrowhead Pharmcaceuticals, Inc. |
Integrin ligands and uses thereof
|
|
DK3719128T3
(da)
|
2017-12-01 |
2025-03-03 |
Suzhou Ribo Life Science Co Ltd |
Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
|
|
EP3719127A4
(en)
|
2017-12-01 |
2021-10-20 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
|
|
CA3083970A1
(en)
|
2017-12-01 |
2019-06-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
|
|
CN110944675B9
(zh)
|
2017-12-01 |
2024-08-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
EP3719126B1
(en)
|
2017-12-01 |
2025-01-01 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
AU2018394875B2
(en)
|
2017-12-29 |
2023-08-03 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
AU2019206731A1
(en)
|
2018-01-15 |
2020-07-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of DNM2 expression
|
|
WO2019157531A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
EP3775211B1
(en)
|
2018-04-12 |
2023-04-05 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
WO2019210308A1
(en)
|
2018-04-27 |
2019-10-31 |
Arrowhead Pharmaceuticals, Inc. |
Integrin targeting ligands and uses thereof
|
|
CU20200082A7
(es)
|
2018-05-09 |
2021-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la reducción de la expresión de fxi
|
|
US12496311B2
(en)
|
2018-07-17 |
2025-12-16 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
EP3833397A4
(en)
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
|
JP7625512B2
(ja)
|
2018-08-13 |
2025-02-03 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
|
|
WO2020038377A1
(zh)
|
2018-08-21 |
2020-02-27 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
TW202542311A
(zh)
|
2018-09-19 |
2025-11-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
WO2020069055A1
(en)
*
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
US11896674B2
(en)
|
2018-09-30 |
2024-02-13 |
Suzhou Ribo Life Science Co., Ltd. |
SiRNA conjugate, preparation method therefor and use thereof
|
|
CR20210395A
(es)
|
2018-12-21 |
2021-11-05 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresión de hsd17b13
|
|
WO2020135673A1
(zh)
|
2018-12-28 |
2020-07-02 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
SG11202105577TA
(en)
|
2019-01-09 |
2021-06-29 |
Arrowhead Pharmaceuticals Inc |
Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
|
|
US20220195428A1
(en)
*
|
2019-01-29 |
2022-06-23 |
The Genera Hospital Corporation |
Oligonucleotides and methods for the treatment of age-related macular degeneration
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
KR20220011689A
(ko)
|
2019-05-22 |
2022-01-28 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
|
|
AU2020280439B2
(en)
|
2019-05-22 |
2025-08-14 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
US12590304B2
(en)
|
2019-05-22 |
2026-03-31 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
CN113795582B
(zh)
|
2019-05-24 |
2024-05-24 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
JP7720788B2
(ja)
*
|
2019-06-25 |
2025-08-08 |
アムジエン・インコーポレーテツド |
炭水化物に連結されたオリゴヌクレオチドのための精製方法
|
|
US20220281911A1
(en)
|
2019-08-19 |
2022-09-08 |
Mina Therapeutics Limited |
Oligonucleotide conjugate compositions and methods of use
|
|
WO2021074772A1
(en)
|
2019-10-14 |
2021-04-22 |
Astrazeneca Ab |
Modulators of pnpla3 expression
|
|
CN120505310A
(zh)
|
2020-02-28 |
2025-08-19 |
Ionis制药公司 |
用于调节smn2的化合物和方法
|
|
CN115916262A
(zh)
|
2020-04-21 |
2023-04-04 |
旗舰创业股份有限公司 |
双官能分子及其使用方法
|
|
LT4136092T
(lt)
|
2020-11-18 |
2024-09-25 |
Ionis Pharmaceuticals, Inc. |
Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui
|
|
TW202305133A
(zh)
|
2021-03-26 |
2023-02-01 |
英商米納治療有限公司 |
Tmem173 sarna組合物及其使用方法
|
|
JP2024516096A
(ja)
|
2021-04-08 |
2024-04-12 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
終末糖化産物受容体の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法
|
|
WO2023034561A2
(en)
*
|
2021-09-02 |
2023-03-09 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
US12042509B2
(en)
|
2021-10-01 |
2024-07-23 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
JP2024535445A
(ja)
*
|
2021-10-08 |
2024-09-30 |
レグルス セラピューティクス インコーポレイテッド |
オフターゲット効果を回避するための方法及び組成物
|
|
WO2023060237A1
(en)
|
2021-10-08 |
2023-04-13 |
Regulus Therapeutics Inc. |
Methods and compositions for treatment of polycystic kidney disease
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
US11879125B2
(en)
|
2022-03-16 |
2024-01-23 |
Empirico Inc. |
GalNAc compositions for improving siRNA bioavailability
|
|
AU2023245603A1
(en)
|
2022-03-28 |
2024-11-07 |
Empirico Inc. |
Modified oligonucleotides
|
|
AU2023408479A1
(en)
|
2022-12-19 |
2025-05-01 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar)
|
|
ES3030929T3
(en)
|
2022-12-19 |
2025-07-02 |
Arnatar Therapeutics Inc |
Arnatar compounds and methods for enhanced cellular uptake
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
TW202448484A
(zh)
|
2023-04-20 |
2024-12-16 |
美商雅迪克斯製藥公司 |
Ｍａｐｔ調節組合物及其使用方法
|
|
WO2024238396A1
(en)
|
2023-05-12 |
2024-11-21 |
Adarx Pharmaceuticals, Inc. |
Nmda ligand conjugated compounds and uses thereof
|
|
CN121335980A
(zh)
|
2023-05-26 |
2026-01-13 |
阿达尔克斯制药有限公司 |
Sod1调节组合物及其使用方法
|
|
EP4562158A1
(en)
|
2023-06-13 |
2025-06-04 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar) for angiotensinogen
|
|
EP4731763A1
(en)
|
2023-06-20 |
2026-04-29 |
Adarx Pharmaceuticals, Inc. |
Lrrk2-modulating compositions and methods of use thereof
|
|
WO2025165891A1
(en)
|
2024-01-29 |
2025-08-07 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
EP4671372A3
(en)
|
2024-01-29 |
2026-03-11 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|